abstract |
The present invention provides an individual who is at or at risk for treating a disease or condition associated with a BRAF V600 mutation or a BRAF fusion mutation, but does not activate a MAPK pathway in a cell containing wild-type BRAF or does not induce a MAPK expression in a cell containing wild-type BRAF Path gene approach. |